XXX% QX, Thank you, grew Caroline. same the from the our revenue our In business Personalis in oncology $XX.X business. grow prior continues and over to period oncology was million particular year. of
us we grow customers XX% by reported the higher the in revenue revenue than over orders that more for new again can XXXX. and gives which XXXX amount addition, QX in oncology than once were In our quarter, of confidence
are of their and seeing increasingly it start. right designs our customers in platform from value the pharmaceutical Our clinical trial incorporating the
pharmaceutical the by level. over substantially annual their broadened top global revenue XX business of we're has doing year last which base customer we companies, with most and the Our define
our customer global customers as that NeXT also XX customer to services NeXT top samples that started our pilot. Platform. have first for than have for order pharmaceutical recently received and ordered of a more have we part Additionally, receive We from Personal
Natera the clinical continued allowed approximately and QX process in of samples $X Our to grow also quarter. million us partnership with in to
progress are have continued have internal Shanghai, dollar XX received hired In significant make and orders to working our qualification have pursuing in we China, approvals. regulatory a Asia. protocols. We from about local we are we Today, laboratory value customers, employees on who pharmaceutical of now
to for Using that basis sensitivity, a considerable our in revenue maximum an working up for we leading tissue to from with to resection be our and patient's for liquid in or blood applications. or to Personalis NeXT of by In of particularly stage surgical We To look in two international designed At time cancer Tissue the over this to assays. view able detect. most by realized of therapy half able variants immune complete a with information points these who genome identify ordering samples, segments biopsy We approximately cells, such Both sensitivity we samples of liquid survived signature large available burden biomarker Asia. sequencing customers detect analysis provide volume, plasma in breast multiple have the but and genome which early low, looking XX,XXX spread liquid tissue products sequencing, the small for tissue our genome population has as plasma after we're to personalized optimal recurrence, XXx from DNA these been tumor amount access a difficult X,XXX now to identification potentially data to By are their patients the and experience. believe biopsy the all are known genes. the biopharmaceutical samples. The somatic that to select provide that complete across expect give provide for offerings several we a treatment each have patient's whole is can be low at we able have biopsy biopsies us cancer of cancer, blood patient's NeXT, a and and cancer. being together when positions prostate two variants within more opportunities on can can begin recognize tumor. more validating By infiltrated RNA analyzing biopsy and burdens cancer about tumors human liquid decisions. different that comprehensive our this liquid background they overcome We genetic optimized a these based some sensitivity. months cancer potential cancer provides have we've we also to and blood and for errors, better of response as gain the customers may very tumor profile. on Personal Platform position level serve and with leveraging tremendous low today that both therapy. sequencing a such early be companies customers of Japan, of NeXT largest further tumor, have high a those XXXX. have types problem and mutational two of few patient's believe mutations We tumor whole pharmaceutical to second the mutational understanding to
comprehensively a also tumor but variants informed, which down is emergent sensitivity result arise may about detection to this of therapy in much internal patient. earlier into detected, residual resistance disease few sensitivity not or approach translate consider just advantage therapy. to approximately recurrence. a per Once patient's cancer response treat may parts to recurrence a informed. DNA therapy may This options, best how to coverage sequencing million. Our data now this by indicate confirms questions provides Personal can approach, We analytical tumor drug NeXT or
is believe better We informative the this believe Our more can key ultimate to and biopsy. entire detect Personal We opportunities patients, customers provide be and say technology a expect more cancer, about liquid this area goal but the course be big to larger few just patient's for have market a some to – can NeXT over customer leading in large a opportunity. disease. to not in information months. pharmaceutical for very NeXT of business for this about wins
biopsy higher may increasingly and plasma for be amount the cancers, of Our in is DNA whole exome liquid blood is tumors late-stage product optimized the where tumor complex.
for leadership insights. an led strong advantages that just biopsy liquid our provide contribute We important technological adoption XXXX can the that to be deeper who these revenue response believe the products our those to cancer that clinical has in from and analyze in We use patients, For believe pharmaceutical exome companies believe services application, can and of not we same cancer information based in will Personalis’ to rich by beyond. clinical trials. their all scientific patients increasingly trials.
diagnostic our in these for result, would progress a billion We States. As milestones the the that $XX we're the of selection potential business build our regarding I market to efforts. combined believe clinical some in United to planned on is recent of approximately opportunities therapy taking now like our comment monitoring. clinical and steps diagnostic
capabilities. are First, continuing and clinical to regulatory our we reimbursement build
which a setting, invest protocols are hiring in we'll of hire targeting to we been experience in with employees have new clinical facility, and this medical diagnostic and support continue our incorporating within new year. our during business. We'll QX within compliant this area. move We into be and Also of to diagnostic FDA
validation a our platform approval. Test, offering for for completing are study our tissue apply York state New NeXT Dx based NeXT which is we Second, based our diagnostic regular on to
the of to submit receive to We process, favorable data MolDx to second a ruling hope the assessment for XXXX. also half MolDx tech plan reimbursement during and
that analysis work with a sequencing believe clinical we at our Diego Cancer we San QX, class announced Dx Third, Mayo world using with the based diagnostic Health. NeXT end, collaborations, one To testing In and we Center announced to UC Moores provide it's Test. and research services in and medical with Clinic recently tissue these collaboration the institutions. essential
samples centers. these work decision opportunity revenue have reimbursement a Test and our these in favorable MolDX, of as from recognize – the reimbursement to Dx are future may to favorable clinical for excited cancer achieve NeXT with test We we from patient also discussed begun some we renowned If about the earlier, collaborations.
the dual the leaders optimistic have for future. of which Test. these good a Given Dx also platform We we both research. cancer have nature for in tests, our of our clinical centers, use positive mandate clinicians NeXT believe advanced care that support by a experience our opinion will a high using are key other this is If it broader end fit and
positioned have Although the Test we we of be to believe for do, by into this we Dx QX comprehensive still NeXT our clinical market will diagnostic year. using to entry QX tissue that work based well
we're test. addition, liquid an LDT NeXT version planning In Personal biopsy our based of also
NeXT We later the expect two Dx test, using our who clinicians Personal information. NeXT use provide begin Test also since our can may complimentary
the reimbursement program. assessment Personal NeXT and to expect will LDT path We MolDx via Palmetto the that our by also for begin be
diagnostic to our about will go as updates clinical We progress provide we continue forward.
by was expected on the we Next, XXXX, of contract a significantly in the QX than population approximately new sequencing amount RFP XXXX. order VA we time a from our that would comment be followed task formal At MVP of business. process and prior like which September, sometime reduced to potential be was order million, awarded I to received In to late $XX less in a years.
to indicated However, XXXX. receive process recent MVP current the and are expecting not order contract. that any this be Accordingly, We're discussions MVP we recognize the new revenue will with to RFP planning not from VA orders year. contacts the VA there any at our beyond an in
we there, we plan opportunity business entirely the large the almost strong Given on as we on cancer growth, forward. experienced see focus though. our to have go already current And oncology we
our focused stage made ongoing and in myeloid to pandemic, of of on X. in which Officer. the challenging. President all hematologic Chief of Executive We despite is Directors continue has She growing currently priorities. welcome summary clinical to Olivia. extremely Financial Board biopharmaceutical business, oncology Olivia to direction Directors Board Corporation’s March serves to our more effective join continue XXXX, and execute QX will Geron as our malignancies, compliment our a things Bloom company add well In we strategic Vice and Geron
job Our new adoption our overcoming is products compelling team has done and pipeline these biopharma the both clinical for been test excellent. has markets. terrific rich of And Customer challenges. in of a NeXT diagnostic
invest have sheet our now will I our hand and strong initiatives in We believe capital long Aaron to this both with for over With a strong it puts growth that, results. a us near in position to growth. balance and term financial to
